Axcelead Drug Discovery Partners and Acadia Pharmaceuticals Launch 2nd Drug Discovery Project in Neuroscience
December 25, 2023 – Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead...
In-Vivo Science and Axcelead DDP Entered into Cooperative Agreement for Drug Discovery Services Using Disease Model Animals
In-Vivo Science, Inc. (Headquarters: Meguro-ku, Tokyo; Branch Office: Kawasaki City, Kanagawa Prefecture; President: Koji Yoshimura; hereinafter “In-Vivo...
Results of joint research with the University of Tokyo published in the international scientific journal “Nature Communications”
Axcelead Drug Discovery Partners Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture; President & CEO: Nobuhiko Yamada; hereinafter “Axcelead...
FRONTEO and Axcelead DDP Sign Master Collaboration Agreement for AI Drug Discovery Support Partnership
FRONTEO Inc. (Headquarters: Minato-ku, Tokyo; President & CEO: Masahiro Morimoto; hereinafter “FRONTEO”) and Axcelead Drug Discovery Partners...
BIO-Europe: Meet us in Munich, Germany
Axcelead will be exhibiting at upcoming BIO-Europe in Munich, Germany. Visit us at Booth #10 to learn how we...
Discovery On Target 2023: Meet us in Boston
Axcelead will be exhibiting at upcoming Discovery On Target 2023 in Boston. Visit us at Booth #200 to learn how we...